Alvotech

Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide.

Alvotech’s true purpose is to make people’s lives better by producing high quality medicines that help people live healthier, and more active lives.

Alvotech was founded in 2013 by Róbert Wessman. The company is headquartered in Reykjavík, Iceland.

 

Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities.

 

Alvotech’s current pipeline contains seven biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer.

 

Alvotech's fully in-house R&D and manufacturing provide a cutting-edge in-house R&D capability, from cell line, process and product development through process scale-up and manufacturing are completed by a fully integrated clinical and regulatory function, allowing a smooth transition.

 

Alvotech is backed by Oaktree Capital Management, CVC Capital Partners, Temasek, Farallon Capital Management, Fuji Pharma, Athos, Arion Bank, and others. The company raised $21M in additional commitments for a private placement (“PIPE”) on Jan 18, 2022. Alvotech has raised a total of over $475M in funding to date. The company is reported to be valued at $2.25B.

 

 

  • Year founded: 2013
  • Funding Info: $475M over 6 Rounds (Latest Funding Type: PIPE)
  • Yearly Revenue: NA
  • Employee Size: 501-1,000
  • Business Valuation: Valued at $2.25B as of Jan 2022
  • City/Town: Reykjavík
  • State: Reykjavík
  • Country: Iceland
Related businesses